4'-oxo-5',6'-dihydro-4'H-spiro[cyclohexane-1,7'-thieno[3,2-c]pyridine]-2'-ylboronic acid | 1321937-16-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并吡啶类
• 英文名称: 4'-oxo-5',6'-dihydro-4'H-spiro[cyclohexane-1,7'-thieno[3,2-c]pyridine]-2'-ylboronic acid
• CAS: 1321937-16-9
• 化学式: C₁₂H₁₆BNO₃S
• 分子量: 265.141
• InChiKey: LBLDEVRGACEVAC-UHFFFAOYSA-N

反应信息

• 作为反应物：
  描述：

  6-chloro-9H-purine 、 4'-oxo-5',6'-dihydro-4'H-spiro[cyclohexane-1,7'-thieno[3,2-c]pyridine]-2'-ylboronic acid 、 三氟乙酸 在 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 sodium carbonate 作用下， 以 乙二醇二甲醚 、 水 、 乙腈 为溶剂， 反应 0.07h， 以0.9 mg的产率得到2'-(9H-purin-6-yl)-5',6'-dihydro-4'H-spiro[cyclohexane-1,7'-thieno-[3,2-c]pyridin]-4'-one trifluoroacetate salt
  参考文献：
  名称：

  3D Pharmacophore Model-Assisted Discovery of Novel CDC7 Inhibitors

  摘要：

  A ligand-based 3D pharmacophore model for serine/threonine kinase CDC7 inhibition was created and successfully applied in the discovery of novel 2-(heteroaryl)-6,7-dihydrothieno[3,2-c]pyridin-4(5H)-ones. The pharmacophore model provided a hypothesis for lead generation missed by docking to a homology model. Medicinal chemistry exploration of the series revealed clear structure-activity relationships consistent with the pharmacophore model and pointed to further optimization opportunities.

  DOI：

  10.1021/ml200029w
• 作为产物：
  描述：

  2'-chloro-5',6'-dihydro-4'H-spiro[cyclohexane-1,7'-thieno[3,2-c]pyridin]-4'-one 在 tris(dibenzylideneacetone)dipalladium(0) chloroform complex 、 potassium acetate 、 联硼酸频那醇酯 、 三环己基膦 作用下， 以 1,4-二氧六环 为溶剂， 反应 0.33h， 以62%的产率得到4'-oxo-5',6'-dihydro-4'H-spiro[cyclohexane-1,7'-thieno[3,2-c]pyridine]-2'-ylboronic acid
  参考文献：
  名称：

  3D Pharmacophore Model-Assisted Discovery of Novel CDC7 Inhibitors

  摘要：

  A ligand-based 3D pharmacophore model for serine/threonine kinase CDC7 inhibition was created and successfully applied in the discovery of novel 2-(heteroaryl)-6,7-dihydrothieno[3,2-c]pyridin-4(5H)-ones. The pharmacophore model provided a hypothesis for lead generation missed by docking to a homology model. Medicinal chemistry exploration of the series revealed clear structure-activity relationships consistent with the pharmacophore model and pointed to further optimization opportunities.

  DOI：

  10.1021/ml200029w